📣 VC round data is live. Check it out!

Lunit Valuation Multiples

Discover Lunit's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like HealthStream, Diagnósticos da América, Yidu Tech, Lumexa Imaging and more.

Lunit Overview

About Lunit

Lunit Inc is a medical AI software company devoted to providing AI-powered total cancer care. Its products comprise of Lunit INSIGHT CXR, AI solution for Chest x-ray; Lunit INSIGHT MMG, AI solution for Mammography; Lunit SCOPE IO, AI-Powered Biomarker for Immuno-Oncology; and Lunit SCOPE PD-L1, AI Solution for PD-L1 Expression.


Founded

2013

HQ

South Korea

Employees

312

Website

lunit.io

Financials (LTM)

Revenue: $60M
EBITDA: ($34M)

EV

$812M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Lunit Financials

Lunit reported last 12-month revenue of $60M and negative EBITDA of ($34M).

In the same LTM period, Lunit generated $60M in gross profit, ($34M) in EBITDA losses, and had net loss of ($38M).

Revenue (LTM)


Lunit P&L

In the most recent fiscal year, Lunit reported revenue of $55M and EBITDA of ($7M).

Lunit is unprofitable as of last fiscal year, with gross margin of 100%, EBITDA margin of (13%), and net margin of (57%).

See analyst estimates for Lunit
LTMLast FY202320242025202620272028
Revenue$60M$55M$17M$36M$55M
Gross Profit$60M$55M$17M$36M$55M
Gross Margin100%100%100%100%100%
EBITDA($34M)($7M)($20M)($41M)($7M)
EBITDA Margin(57%)(13%)(124%)(114%)(13%)
EBIT Margin(79%)(100%)(168%)(125%)(100%)
Net Profit($38M)($31M)($24M)($55M)($31M)
Net Margin(64%)(57%)(147%)(152%)(57%)
Net Debt-$52M---

Financial data powered by Morningstar, Inc.

Lunit Stock Performance

Lunit has current market cap of $741M, and enterprise value of $812M.

Market Cap Evolution


Lunit's stock price is $9.97.

Lunit share price decreased by 10.5% in the last 30 days, and by 74.2% in the last year.

Lunit has an EPS (earnings per share) of $-0.42.

See more trading valuation data for Lunit
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$812M$741M-6.2%-10.5%-55.0%-74.2%$-0.42

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Lunit Valuation Multiples

Lunit trades at 13.5x EV/Revenue multiple, and (23.7x) EV/EBITDA.

See NTM and 2027E valuation multiples for Lunit

EV / Revenue (LTM)


Lunit Financial Valuation Multiples

As of June 3, 2026, Lunit has market cap of $741M and EV of $812M.

Lunit has a P/E ratio of (19.3x).

LTMLast FY202320242025202620272028
EV/Revenue13.5x14.8x48.9x22.6x14.8x
EV/EBITDA(23.7x)(113.5x)(39.6x)(19.8x)(113.5x)
EV/EBIT(17.2x)(14.8x)(29.1x)(18.1x)(14.8x)
EV/Gross Profit13.5x14.8x48.9x22.6x14.8x
P/E(19.3x)(23.8x)(30.4x)(13.6x)(23.6x)
EV/FCF(22.7x)(22.0x)(32.2x)(17.0x)(18.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Lunit Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Lunit Margins & Growth Rates

Lunit grew revenue by 23% and EBITDA by 235% in the last fiscal year.

In the most recent fiscal year, Lunit reported gross margin of 100%, EBITDA margin of (13%), and net margin of (57%).

See estimated margins and future growth rates for Lunit

Lunit Margins

Last FY202420252026202720282029
Gross Margin100%100%100%100%
EBITDA Margin(13%)(114%)(13%)(35%)
EBIT Margin(100%)(125%)(100%)(55%)
Net Margin(57%)(152%)(57%)(71%)
FCF Margin(67%)(134%)(78%)(51%)

Lunit Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth23%116%53%23%
Gross Profit Growth23%116%53%23%
EBITDA Growth235%100%(83%)235%
EBIT Growth(32%)60%23%(33%)
Net Profit Growth55%124%(43%)54%
FCF Growth(7%)90%(10%)(20%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Lunit Operational KPIs

Lunit's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.4M for the same period.

Lunit's Rule of 40 is (13%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Lunit's Rule of X is 21% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Lunit
LTMLast FY202320242025202620272028
Rule of 40(35%)(13%)---
Bessemer Rule of X(2%)21%---
Revenue per Employee-$0.2M---
Opex per Employee-$0.4M---
S&M Expenses to Revenue-24%45%40%24%
G&A Expenses to Revenue-7%13%9%7%
R&D Expenses to Revenue-50%66%50%50%
Opex to Revenue-200%268%225%200%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
HealthStream2.2x2.2x9.5x9.3x
Diagnósticos da América0.9x1.0x5.0x5.0x
Yidu Tech4.0x-(31.6x)-
Lumexa Imaging1.6x1.6x7.1x7.0x
Craneware3.4x3.1x10.7x10.0x
RaySearch Labs5.2x5.2x12.0x11.7x
Lumibird2.9x2.9x15.0x13.9x
Equasens2.3x2.3x7.8x8.1x

This data is available for Pro users. Sign up to see all Lunit competitors and their valuation data.

Start Free Trial

Lunit VC Funding History

Before going public, Lunit raised $137M in total equity funding, across 7 rounds.

Last private valuation of Lunit was $153M, after raising $26M in December 2019 from IMM Investment, InterVest Co., Kakao Ventures, and 4 other investors.


Lunit Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Nov-21Undisclosed stageBrightEdge; Casdin Capital; HealthQuest Capital; IMM Investment; Kakao Ventures; Legend Capital; Mirae Asset Venture Investment; NAVER; Naver Cloud; NSG Ventures; SBVA; Tybourne Capital Management$61M-Lunit, a South Korean medical AI provider founded in 2013, develops AI-powered diagnostic tools for cancer detection, including Lunit INSIGHT MMG for breast cancer mammography and INSIGHT CXR for chest x-rays. The company raised $61 million in a pre-IPO funding round announced on November 25, 2021, ahead of a planned KOSDAQ listing early the following year. New investors included US life science firms HealthQuest Capital ($20M), Casdin Capital, and American Cancer Society BrightEdge, plus Asia-based Tybourne Capital Management and NSG Ventures. Existing participants were Naver, Naver Cloud, Softbank Ventures Asia (SBVA), Legend Capital, IMM Investment, Kakao Ventures, and Mirae Asset Venture Investment. This round followed a $26 million strategic investment from Guardant Health in July 2021, bringing Lunit's total funding to over $135 million. The investments aimed to secure strategic partners for growth in conquering cancer through AI, as stated by CEO Brandon Suh. HealthQuest Capital's participation highlighted validation from a leading healthcare growth equity firm. Lunit had recent regulatory wins, including US FDA 510(k) clearance for INSIGHT MMG to detect breast cancer lesions via heatmaps and outlines. Partnerships included rollout of INSIGHT CXR and MMG with Singapore's RadLink and integration into Fujifilm's CXR-AID, approved in Japan. These developments positioned Lunit as a leader in medical AI ahead of its IPO.
Jul-21Series CGuardant Health$26M-Lunit, a South Korea-based AI software company specializing in precision diagnostics and therapeutics for cancer through AI-powered radiology and pathology solutions like Lunit SCOPE and Lunit INSIGHT, secured a $26 million strategic investment from Guardant Health on July 19, 2021, closing its Series C Tranche B funding round. This investment also established a groundbreaking collaboration between Guardant Health, a precision oncology firm focused on liquid biopsy, and Lunit to innovate in cancer diagnosis and treatment, including joint products like Lunit SCOPE PD-L1 TPS under Guardant Galaxy. The funding aimed to advance Lunit's AI work for clinical use and reshape the precision oncology landscape. Guardant Health led the round as the sole investor mentioned in primary announcements, with Lunit planning to file for a KOSDAQ IPO later that year. Some secondary sources reference additional Asian investors like Shinhan Investment, InterVest, IMM Investment, Kakao Ventures, and Legend Capital, but press releases emphasize Guardant Health's role. Lunit highlighted its technology's potential, noting at ASCO 2021 that Lunit SCOPE identified 50% more immunotherapy responders than traditional pathology. Following this, Lunit raised a $61 million pre-IPO round led by HealthQuest Capital and others, bringing total funding over $135 million ahead of its planned public offering. The company later achieved FDA clearances for products like Lunit INSIGHT CXR Triage and MMG, and received milestone payments from Guardant Health.
Dec-19Series CIMM Investment; InterVest Co.; Kakao Ventures; Legend Capital; LG CNS; NH Investment & Securities; Shinhan Financial Group$26M$153M-
Nov-19Series BFUJIFILM$4M$129MLunit is a South Korean med-tech company founded in 2013, specializing in AI-based cancer diagnostics software, including solutions for chest X-ray and mammography analysis. The company develops AI-powered diagnostic tools and biomarkers to predict patient responses to cancer therapies, with products like Lunit INSIGHT commercially available in over 30 countries through partnerships with GE Healthcare, Philips, and Fujifilm. In late 2019, Lunit received a Series B1 investment led by Fujifilm valued at $5 million, following earlier rounds including Series A ($2 million) and Series A1 ($3.3 million) led by Softbank Ventures Asia. This came alongside partnerships such as the Fujifilm agreement and regulatory clearances from the Ministry of Korea Food and Drug Safety for Lunit INSIGHT CXR-Nodule and MMG. BioWorld reported in January 2020 that Lunit’s corporate value reached as much as ₩200 billion ($25.6 million equivalent at series C), with total funding at that point at $50 million. Lunit established a US subsidiary and continued expanding its AI solutions, achieving FDA clearance for key products in subsequent years.
Jul-18Series BFormation 8; InterVest Co.; Kakao Ventures; KT Investment; Legend Capital; Mirae Asset Venture Investment; SBVA$15M-Lunit, an AI healthcare startup based in Seoul, South Korea, develops deep-learning technology for medical imaging to improve diagnosis accuracy. In July 2018, Lunit raised $15 million in its Series B funding round led by InterVest Co., with participation from Formation 8, Kakao Ventures, KT Investment, Legend Capital, Mirae Asset Venture Investment, and SBVA. The funds were allocated to accelerate growth in AI healthcare software, develop new deep-learning technologies in medical imaging, expand operations, and hire talent. Lunit planned to present its business at SoftBank World 2018 in Tokyo.
Aug-16Series AInterVest Co.; Kakao Ventures; Mirae Asset Venture Investment; SBVA$3M--
Nov-15Series AFormation 8; Kakao Ventures; SBVA$2M--

Acquisitions by Lunit

Lunit has acquired 1 company to date.

Last acquisition by Lunit was on December 14th 2023. Lunit acquired Volpara Health for $193M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Lunit

Volpara Health
Description
Volpara Health is a Seattle-headquartered developer of AI-driven software for breast cancer screening and risk assessment. The platform analyzes mammograms to quantify breast density, identify masking risk, and recommend personalized screening pathways for radiologists worldwide. Listed on the ASX, Volpara integrates with systems from GE Healthcare, Hologic, and Siemens Healthineers across North America, Europe, and Asia-Pacific.
HQ CountryNew Zealand
HQ City
Wellington
Deal Date14 Dec 2023
Valuation$193M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Lunit acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Lunit

When was Lunit founded?Lunit was founded in 2013.
Where is Lunit headquartered?Lunit is headquartered in South Korea.
How many employees does Lunit have?As of today, Lunit has over 312 employees.
Is Lunit publicly listed?Yes, Lunit is a public company listed on Korea Exchange.
What is the stock symbol of Lunit?Lunit trades under 328130 ticker.
When did Lunit go public?Lunit went public in 2022.
Who are competitors of Lunit?Lunit main competitors include HealthStream, Diagnósticos da América, Yidu Tech, Lumexa Imaging, Craneware, RaySearch Labs, Lumibird, Equasens, Echo IQ, Jiangsu Bioperfectus.
What is the current market cap of Lunit?Lunit's current market cap is $741M.
What is the current revenue of Lunit?Lunit's last 12 months revenue is $60M.
What is the current revenue growth of Lunit?Lunit revenue growth (NTM/LTM) is 22%.
What is the current EV/Revenue multiple of Lunit?Current revenue multiple of Lunit is 13.5x.
Is Lunit profitable?No, Lunit is not profitable.
What is the current EBITDA of Lunit?Lunit has negative EBITDA and is not profitable.
What is Lunit's EBITDA margin?Lunit's last 12 months EBITDA margin is (57%).
What is the current EV/EBITDA multiple of Lunit?Current EBITDA multiple of Lunit is (23.7x).
What is the current FCF of Lunit?Lunit's last 12 months FCF is ($36M).
What is Lunit's FCF margin?Lunit's last 12 months FCF margin is (60%).
What is the current EV/FCF multiple of Lunit?Current FCF multiple of Lunit is (22.7x).
How many companies Lunit has acquired to date?As of June 2026, Lunit has acquired 1 company.
What was the largest acquisition by Lunit?$193M acquisition of Volpara Health on 14th December 2023 was the largest M&A Lunit has done to date.
What companies Lunit acquired?Lunit acquired Volpara Health.
In how many companies Lunit has invested to date?Lunit hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Lunit

Lists including Lunit

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial